Possible synergies between isatin, an endogenous MAO inhibitor, and antiparkinsonian agents on the dopamine release from striatum of freely moving rats

• Published in: Neuropharmacology Vol. 171; p. 108083
• Main Authors: Faro, Lilian R.F., Justo, Lorenzo A., Alfonso, Miguel, Durán, Rafael
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2020
• Subjects: Antiparkinsonian agents; Dopamine; In vivo cerebral microdialysis; Isatin; Synergies; In vivo cerebral microdialysis; Dopamine; Isatin; Synergies; Antiparkinsonian agents
• ISSN: 0028-3908; 1873-7064
• DOI: 10.1016/j.neuropharm.2020.108083

Isatin is an endogenous indole that inhibits monoamine oxidase (MAO). When exogenously administered, it increases the striatal dopamine and acetylcholine levels and presents neuroprotective effects in the brain. Previous studies show that intrastriatal administration of isatin increased the in vivo dopamine release from striatum in a concentration-dependent form. In the present work, we investigated the effects of combined administration of isatin together with other substances actually used in antiparkinsonian pharmacotherapy on in vivo dopamine overflow. For this, we co-administered isatin with the MAO inhibitors selegiline and clorgyline, l-DOPA, the catechol-o-methyl-transferase (COMT) inhibitors tropolone and dinitrocatechol, with the dopaminergic agonist ropinirole, and with the psychostimulant caffeine, in order to evaluate possible synergies between these substances to increase the dopamine extracellular levels in freely moving rats. Intrastriatal administration of isatin (10 mM, 60 min) significantly increased dopamine release to 1164 ± 152%, compared to the baseline. Co-administration of isatin together with selegiline (1 mM) or clorgyline (1 mM) alone or in combinations showed a similar profile to increase in vivo dopamine release. Intrastriatal infusion of isatin together with antiparkinsonian drugs l-DOPA (25 μM), tropolone (1 mM), dinitrocatechol (100 μM), amantadine (5 mM) and caffeine (5 mM) significantly elevated extracellular dopamine levels more than any single drug, showing a good neurochemical synergy by improving the effect of isatin on the extracellular dopamine levels in the striatum. Infusion of isatin + ropinirole (5 mM) did not change the isatin-induced increase in dopamine overflow. These results could be useful to carry out further investigations with a possible clinical application. •Isatin increases dopamine levels in a similar profile to selegiline and clorgyline.•Isatin together with l-DOPA shows a good synergistic effect on dopamine levels.•The administration of isatin and COMT inhibitors improves the dopamine levels.•The administration of a dopamine agonist does not modify the effect of isatin.•Amantadine and caffeine improves the effect of isatin on dopamine levels.